K
Kori Wallace
Researcher at AbbVie
Publications - 23
Citations - 915
Kori Wallace is an academic researcher from AbbVie. The author has contributed to research in topics: Crohn's disease & Medicine. The author has an hindex of 6, co-authored 11 publications receiving 567 citations.
Papers
More filters
Journal ArticleDOI
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial
Jean-Frederic Colombel,Remo Panaccione,Peter Bossuyt,Milan Lukas,Filip Baert,Tomáš Vaňásek,Ahmet Danalioglu,Gottfried Novacek,Alessandro Armuzzi,Xavier Hébuterne,Simon Travis,Silvio Danese,Walter Reinisch,William J. Sandborn,Paul Rutgeerts,Daniel W. Hommes,Stefan Schreiber,Ezequiel Neimark,Bidan Huang,Qian Zhou,Paloma Mendez,J Petersson,Kori Wallace,Anne M. Robinson,Roopal Thakkar,Geert R. D'Haens +25 more
TL;DR: This trial aimed to compare endoscopic and clinical outcomes in patients with moderate to severe Crohn's disease who were managed with a tight control algorithm, using clinical symptoms and biomarkers, versus patients management with a clinical management algorithm.
Journal ArticleDOI
Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.
Brian G. Feagan,Julián Panés,Marc Ferrante,Arthur Kaser,Geert R. D'Haens,William J. Sandborn,Edouard Louis,Markus F. Neurath,Denis Franchimont,Olivier Dewit,Ursula Seidler,Kyung-Jo Kim,Christian P. Selinger,Steven J. Padula,Ivona Herichova,Anne M. Robinson,Kori Wallace,Jun Zhao,Mukul Minocha,Ahmed A. Othman,Adina Soaita,Sudha Visvanathan,David B. Hall,Wulf O. Böcher +23 more
TL;DR: Risankizumab was well tolerated with no new safety signals noted and clinical remission was maintained in 44 (71%) patients; 50 (81%) patients had a clinical response, 22 (35%) patients were in endoscopic remission, and 34 (55%) patientshad an endoscopic response.
Journal ArticleDOI
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials
Geert R. D'Haens,Remo Panaccione,Filip Baert,Patrick M.M. Bossuyt,Jean-Frederic Colombel,Silvio Danese,Marla Dubinsky,Brian G. Feagan,Tadakazu Hisamatsu,Allen Lim,James O. Lindsay,Edward V. Loftus,Julián Panés,Laurent Peyrin-Biroulet,Zhihua Ran,David T. Rubin,William J. Sandborn,Stefan Schreiber,Ezequiel Neimark,An Song,Kristina Kligys,Yinuo Pang,Valerie L. Pivorunas,Sofie Berg,W. Rachel Duan,Bidan Huang,Jasmina Kalabic,Xiaomei Liao,Anne M. Robinson,Kori Wallace,Marc Ferrante +30 more
TL;DR: All coprimary endpoints at week 12 were met in both trials with both doses of risankizumab, and the intention-to-treat population (all eligible patients who received at least one dose of study drug in the 12-week induction period) was analysed for efficacy outcomes.
Journal ArticleDOI
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial
Marc Ferrante,Remo Panaccione,Filip Baert,Patrick M.M. Bossuyt,Jean-Frederic Colombel,Silvio Danese,Marla Dubinsky,Brian G. Feagan,Tadakazu Hisamatsu,A. Lim,James O. Lindsay,Edward V. Loftus,Julián Panés,Laurent Peyrin-Biroulet,Zhihua Ran,David T. Rubin,William J. Sandborn,Stefan Schreiber,Ezequiel Neimark,An Song,Kristina Kligys,Yinuo Pang,Valerie L. Pivorunas,Sofie Berg,W. Rachel Duan,Bidan Huang,Jasmina Kalabic,Xiaomei Liao,Anne M. Robinson,Kori Wallace,Geert R. D'Haens +30 more
TL;DR: Subcutaneous risankizumab is a safe and efficacious treatment for maintenance of remission in patients with moderately to severely active Crohn's disease and offers a new therapeutic option for a broad range of patients by meeting endpoints that might change the future course of disease.
Journal ArticleDOI
Selective IL-23 Inhibition by Risankizumab Modulates the Molecular Profile in the Colon and Ileum of Patients With Active Crohn's Disease: Results From a Randomised Phase II Biopsy Sub-study
Sudha Visvanathan,Patrick Baum,Azucena Salas,Richard Vinisko,Ramona Schmid,Kristie M. Grebe,Justin W. Davis,Kori Wallace,Wulf O. Böcher,Steven J. Padula,Jay S. Fine,Julián Panés +11 more
TL;DR: Colonic transcriptomic profiles following risankizumab treatment reflected the transcriptomic changes observed in patients achieving endoscopic response and remission at Week 12 and were significantly different from placebo, indicative of suppression of pathways associated with epithelial biology.